Ubamatamab

Phase 2Monoclonal antibody

Regeneron

Ubamatamab is one of 57 small molecule programs targeting Recurrent Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent Ovarian CancerRecruiting

SMARCB1-Deficient MalignanciesActive, not recruiting

Ovarian CancerRecruiting

Recurrent Ovarian CancerPreclinical

Recruiting

SMARCB1-Deficient MalignanciesPhase 2

Active, not recruiting

Ovarian CancerPhase 2

Recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

88 2

Gemzar

Johnson & Johnson

Phase 3

33 3

Keytruda

Merck & Co.

Phase 3

28 4

Hycamtin

MMeitheal

Phase 3

26 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 6

Opdivo

Bristol-Myers Squibb

Phase 3

8 7

Femara

Novartis

Phase 3

8 8

Imfinzi

AstraZeneca

Phase 3

8 9

Adriamycin

Pfizer

Phase 3

8 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Recurrent Ovarian Cancer

NCT03564340

Q4 2027

PreclinicalRecruiting

Ovarian Cancer

NCT04590326

Q2 2028

Phase 2Recruiting

Ovarian Cancer

NCT06787612

Q3 2028

Phase 2Active, not recruiting

SMARCB1-Deficient Malignancies

NCT06444880

Clinical

Trials by Indication[1]

Ovarian Cancer3 trials

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT06787612·297 enrolled

A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT04590326·612 enrolled

A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer With Poor Response to First-Line Chemotherapy

Not yet recruiting·AARCAGY/ GINECO GROUP·Preclinical·NCT07637851·43 enrolled

Recurrent Ovarian Cancer1 trial

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT03564340·890 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07154290·300 enrolled

SMARCB1-Deficient Malignancies1 trial

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06444880·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ubamatamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ubamatamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ubamatamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Regeneron

Ubamatamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Ovarian Cancer3 trials

Recurrent Ovarian Cancer1 trial

Non-Small Cell Lung Cancer1 trial

SMARCB1-Deficient Malignancies1 trial

References

Drug Info

Quick Facts

Related News